New treatments for advanced pancreatic cancer are leading to better outcomes and allowing patients to go on maintenance therapy. In this activity, an expert panel reviews recent clinical evidence and guideline-based selection of appropriate therapies. The case-based discussion covers germline and somatic testing for biomarkers, selection of first- and later-line agents, novel and emerging therapies, and management of disease-related symptoms and treatment-related adverse events. Use of an individualized approach and improving patient adherence and are also emphasized.
Interactive video lecture
After completing this activity, participants should be better able to:
- Summarize recent findings on the use of biomarkers in pancreatic cancer
- Identify the appropriate use of newer therapies for pancreatic cancer based on efficacy and safety data and patient factors
- Implement strategies to address treatment-related adverse events and promote adherence among patients with pancreatic cancer
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Kelley A. Rone, DNP, Mayo Clinic, Phoenix, Arizona
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 19, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a live program cosupported by educational grants from AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck & Co., Inc.; and Taiho Oncology, Inc.
This activity is supported by an educational grant from Bristol-Meyers Squibb.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Bekaii-Saab: advisory board: Immuneering, Imugene, Sun BioPharma; consultant: AbbVie, BeiGene, Boehringer Ingelheim, Celularity, Daichii Sankyo, Eisai, Exact Sciences, Foundation Medicine, Janssen, Natera, Sobi, Treos Bio, Xilis; consultant/DSMB member: AstraZeneca; consultant/research support: Array BioPharma, Bayer, Genentech, Incyte, Ipsen, Merck, Pfizer, Seattle Genetics; DSMB member: 1Globe Health Institute, Exelixis, PanCAN; DSMB member/research support: Lilly; research support: AbGenomics, Agios, Amgen, Arys, Boston Biomedical, Bristol-Myers Squibb, Celgene, Clovis Oncology, Merus, Mirati Therapeutics, Novartis.
Dr McGrath has no relevant financial relationships to disclose.
Dr Pishvaian: consultant: AstraZeneca, Foundation Medicine, Halozyme, Merck; consultant/stock: Perthera.
Dr Wang-Gillam: consultant: Arotech, Bayer, InxMed, Merck; employee: Jacobio Pharmaceuticals.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 20, 2021
Expiration date: March 19, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100320BTC-7C